Zions Bancorporation National Association UT Acquires 2,726 Shares of Thermo Fisher Scientific Inc. $TMO

Zions Bancorporation National Association UT lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.5% during the third quarter, HoldingsChannel reports. The firm owned 12,639 shares of the medical research company’s stock after purchasing an additional 2,726 shares during the period. Zions Bancorporation National Association UT’s holdings in Thermo Fisher Scientific were worth $6,130,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of TMO. Brighton Jones LLC raised its holdings in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Nordea Investment Management AB grew its stake in Thermo Fisher Scientific by 5.9% in the second quarter. Nordea Investment Management AB now owns 63,191 shares of the medical research company’s stock valued at $25,979,000 after purchasing an additional 3,512 shares during the last quarter. Stratos Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 3.4% during the second quarter. Stratos Wealth Advisors LLC now owns 2,406 shares of the medical research company’s stock valued at $976,000 after buying an additional 79 shares during the last quarter. Finally, Curbstone Financial Management Corp boosted its holdings in shares of Thermo Fisher Scientific by 3.8% in the 2nd quarter. Curbstone Financial Management Corp now owns 1,366 shares of the medical research company’s stock valued at $554,000 after buying an additional 50 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. Evercore restated an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, January 5th. Robert W. Baird set a $653.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a research report on Friday, January 30th. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective for the company in a research note on Sunday, December 7th. Finally, Argus upped their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $633.68.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total value of $18,668,480.00. Following the transaction, the chief operating officer directly owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This trade represents a 32.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 108,996 shares of company stock valued at $63,355,935. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.9%

Shares of TMO stock opened at $504.99 on Monday. The stock has a 50 day simple moving average of $585.45 and a 200-day simple moving average of $545.03. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a market cap of $189.73 billion, a price-to-earnings ratio of 28.47, a PEG ratio of 2.91 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm’s revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.10 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.